Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
| Revenue (Most Recent Fiscal Year) | $31.91M |
| Net Income (Most Recent Fiscal Year) | $-26.08M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.07 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.67 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -26.11% |
| Net Margin (Trailing 12 Months) | -73.25% |
| Return on Equity (Trailing 12 Months) | -10.98% |
| Return on Assets (Trailing 12 Months) | -7.48% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.04 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.69 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 2.42 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.09 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Common Shares Outstanding | 52.40M |
| Free Float | 46.43M |
| Market Capitalization | $31.18M |
| Average Volume (Last 20 Days) | 0.06M |
| Beta (Past 60 Months) | 1.06 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 11.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 36.90% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |